Therefore, while the primary goal of NBS programs is to improve outcomes for the screened babies, our preliminary results indicate that NBS for SMA has the potential to also identify heterozygous carriers of one SMN1 copy that, based on the disease frequency, are usually unaffected. Here, SMN1 is linked to proximal spinal muscular atrophy.